Evaluation of the Humoral Immune Response of a Heterologous Vaccination between BBIBP-CorV and BNT162b2 with a Temporal Separation of 7 Months, in Peruvian Healthcare Workers with and without a History of SARS-CoV-2 Infection

Miguel Hueda-Zavaleta, Juan C. Gómez de la Torre, José Alonso Cáceres-Del Aguila, Cecilia Muro-Rojo, Nathalia De La Cruz-Escurra, Daniella Arenas Siles, Diana Minchón-Vizconde, Cesar Copaja-Corzo, Fabrizzio Bardales-Silva, Vicente A. Benites-Zapata, Alfonso J. Rodriguez-Morales

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Information on the effects of a heterologous booster in adult patients first vaccinated with the BBIBP-CorV vaccine is limited. This prospective cohort study evaluated the humoral response of 152 healthcare workers (HCWs) from a private laboratory in Lima (Peru) before and after receiving the BNT162b2 vaccine, with a seven-month interval since the BBIBP-CorV doses. We employed the Elecsys® anti-SARS-CoV-2 S and the cPass™ SARS-CoV-2 Neutralization Antibody (NAbs) assays to evaluate anti-S-RBD IgG and NAbs, respectively. Of the 152 HCWs, 79 (51.98%) were previously infected (PI) with SARS-CoV-2 and 73 (48.02%) were not previously infected (NPI). The proportion of HCWs with positive NAbs, seven months after the BBIBP-CorV immunization, was 49.31% in NPI and 92.40% in PI. After the booster, this ratio increased to 100% in both groups. The anti-S-RBD IgG and NAbs in the HCWs’ NPI increased by 32.7 and 3.95 times more, respectively. In HCWs’ PI, this increment was 5 and 1.42 times more, respectively. There was no statistical association between the history of previous SARS-CoV-2 infection and the titer of anti-S-RBD IgG and NAbs after the booster. The humoral immunity presented a robust increase after receiving the BNT162b2 booster and was more pronounced in NPI.

Original languageEnglish
Article number502
JournalVaccines
Volume10
Issue number4
DOIs
StatePublished - Apr 2022

Keywords

  • COVID-19 vaccines
  • heterologous booster vaccination
  • humoral immunity
  • neutralizing antibodies
  • SARS-CoV-2

Fingerprint

Dive into the research topics of 'Evaluation of the Humoral Immune Response of a Heterologous Vaccination between BBIBP-CorV and BNT162b2 with a Temporal Separation of 7 Months, in Peruvian Healthcare Workers with and without a History of SARS-CoV-2 Infection'. Together they form a unique fingerprint.

Cite this